Pharmaron Beijing - Public Comps and Valuation Multiples

Pharmaron Beijing Overview

About Pharmaron Beijing

Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.

Founded

2004

HQ

Employees

21.4K+

Website

pharmaron.com

Sectors

Contract Research & Manufacturing
Laboratory Services
BioTech

Financials

LTM Revenue $2.0B

LTM EBITDA $495M

EV

$8.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Pharmaron Beijing Financials

As of December 2025, Pharmaron Beijing reported last 12-month revenue of $2.0B and EBITDA of $495M.

In the same period, Pharmaron Beijing generated $701M in LTM gross profit and $246M in net income.

See Pharmaron Beijing valuation multiples based on analyst estimates

Pharmaron Beijing P&L

In the most recent fiscal year, Pharmaron Beijing reported revenue of $1.8B and EBITDA of $484M.

Pharmaron Beijing expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Pharmaron Beijing valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$2.0B	XXX	$1.8B	XXX	XXX	XXX
Gross Profit	$701M	XXX	$601M	XXX	XXX	XXX
Gross Margin	35%	XXX	34%	XXX	XXX	XXX
EBITDA	$495M	XXX	$484M	XXX	XXX	XXX
EBITDA Margin	25%	XXX	28%	XXX	XXX	XXX
EBIT	$307M	XXX	$266M	XXX	XXX	XXX
EBIT Margin	15%	XXX	15%	XXX	XXX	XXX
Net Profit	$246M	XXX	$256M	XXX	XXX	XXX
Net Margin	12%	XXX	15%	XXX	XXX	XXX
Net Debt	XXX	XXX	$493M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Pharmaron Beijing including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $2.0B. EBITDA for the last twelve months was $495M. In the most recent fiscal year, Pharmaron Beijing achieved $1.8B in revenue and $484M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$2.0B	Analyst estimates available to subscribers	$1.8B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$701M	Analyst estimates available to subscribers	$601M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	34.9% gross margin	Analyst estimates available to subscribers	34.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$495M	Analyst estimates available to subscribers	$484M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	24.7% EBITDA margin	Analyst estimates available to subscribers	27.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$307M	Analyst estimates available to subscribers	$266M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	15.3% EBIT margin	Analyst estimates available to subscribers	15.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$246M	Analyst estimates available to subscribers	$256M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	12.3% net profit margin	Analyst estimates available to subscribers	14.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$493M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Pharmaron Beijing

This financial data table provides comprehensive performance metrics for Pharmaron Beijing, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Pharmaron Beijing generated $2.0B in revenue over the last twelve months.
The company achieved $495M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $701M.
Net income over the last twelve months reached $246M.

Fiscal Year Performance

In the most recent fiscal year, Pharmaron Beijing reported $1.8B in total revenue.
Fiscal year EBITDA was $484M.
The company maintained a gross profit margin of 34.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was 27.6%.
Net profit margin reached 14.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Pharmaron Beijing. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Pharmaron Beijing Stock Performance

Pharmaron Beijing has current market cap of CNY 53.3B (or $7.6B), and EV of CNY 57.4B (or $8.2B).

Market Cap Evolution

Pharmaron Beijing Stock Data

As of January 16, 2026, Pharmaron Beijing's stock price is CNY 30 (or $4).

See Pharmaron Beijing trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$8.2B	$7.6B	XXX	XXX	XXX	XXX	$0.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Pharmaron Beijing Valuation Multiples

Pharmaron Beijing's trades at 4.1x EV/Revenue multiple, and 16.6x EV/EBITDA.

See valuation multiples for Pharmaron Beijing and 15K+ public comps

Pharmaron Beijing Financial Valuation Multiples

As of January 16, 2026, Pharmaron Beijing has market cap of $7.6B and EV of $8.2B.

Equity research analysts estimate Pharmaron Beijing's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Pharmaron Beijing has a P/E ratio of 31.0x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$7.6B	XXX	$7.6B	XXX	XXX	XXX
EV (current)	$8.2B	XXX	$8.2B	XXX	XXX	XXX
EV/Revenue	4.1x	XXX	4.1x	XXX	XXX	XXX
EV/EBITDA	16.6x	XXX	16.6x	XXX	XXX	XXX
EV/EBIT	26.7x	XXX	26.7x	XXX	XXX	XXX
EV/Gross Profit	11.7x	XXX	n/a	XXX	XXX	XXX
P/E	31.0x	XXX	31.0x	XXX	XXX	XXX
EV/FCF	35.4x	XXX	35.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Pharmaron Beijing Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Pharmaron Beijing Margins & Growth Rates

Pharmaron Beijing's last 12 month revenue growth is 15%

Pharmaron Beijing's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $16K for the same period.

Pharmaron Beijing's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pharmaron Beijing's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Pharmaron Beijing and other 15K+ public comps

Pharmaron Beijing Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	15%	XXX	15%	XXX	XXX	XXX
EBITDA Margin	25%	XXX	25%	XXX	XXX	XXX
EBITDA Growth	18%	XXX	8%	XXX	XXX	XXX
Rule of 40	40%	XXX	40%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	62%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$16K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	19%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial